Navigation Links
BIO Ventures for Global Health Chosen to Administer the GSK and Alnylam Intellectual Property Pool
Date:1/20/2010

Washington, Jan. 20 /PRNewswire-USNewswire/ -- BIO Ventures for Global Health, GlaxoSmithKline (GSK), and Alnylam announced today that the organizations are partnering to engage the global health community in using the powerful resources of the GSK and Alnylam Intellectual Property (IP) Pool.  The IP Pool was formed in February 2009 to aid in the discovery and development of new medicines for the treatment of 16 neglected tropical diseases, as defined by the U.S. Food and Drug Administration, in the world's least developed countries.  By adopting a more accessible approach to intellectual property, the pool facilitates access to compounds and technologies and, most importantly, industrial know-how for organizations that want to conduct research on treatments for these neglected diseases.

"New medicines for diseases that primarily affect the poor in developing countries have been slow in coming because although the market is large in numbers, most of the people affected and their governments cannot afford to pay even moderate prices. This means that much of the development of new medicines is taking place in innovative non-profits and academic research centers," says Melinda Moree, Chief Executive Officer of BIO Ventures for Global Health, an independent, non-profit organization.  "For many of these academic and global health non-profit groups, however, intellectual property can be perceived as preventing rather than enabling their work. I am excited to use this new role to help those working on developing products for neglected diseases speed up their efforts by accessing the patents, technologies, and product development expertise available in the IP Pool."

As the pool's administrator, BIO Ventures for Global Health will organize disease-specific meetings that identify the gaps i
'/>"/>

SOURCE BIO Ventures for Global Health
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Syngenta Ventures Invests in U.S. Biotech Company Metabolon
2. RiversEdge BioVentures LLC to Provide Advisory and Investment Services in Life Sciences
3. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
4. Health Robotics Expands and Diversifies Global Channel Strategies With Joint-Ventures & Direct Operations
5. BIO Ventures for Global Health Announces Management Changes
6. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
7. Apex Bioventures Acquisition Corporation Receives Notice of Extension from NYSE Amex
8. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
9. Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc
10. Index Ventures Closes Euro 350 Million Early Stage Fund
11. Newbridge Securities Corporation Forms BioVentures Division
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Follow us on LinkedIn –Cholesterol ... cholesterol carrier or lipoprotein in the blood. Such tests ... in the body, especially along the walls of blood ... other cardiovascular disorders. Cardiovascular Diseases (CVD) is the leading ... on a regular basis, to assess an individual’s risk ...
(Date:9/30/2014)... 2014 CORD:USE Cord Blood Bank – ... has entered into an Equity and Exclusive Services Agreement ... series of patented technologies for the isolation of human ... Tianhe is performing Phase I/II clinical trials in ... using Tianhe,s Stem Cell Educator Therapy showing that ...
(Date:9/30/2014)... Switzerland (PRWEB) September 30, 2014 ... software solutions for drug discovery and related ... FUNGITECT consortium has chosen Genedata Selector as ... sequencing (NGS) data. FUNGITECT is a European ... invasive fungal diseases via individualized anti-fungal drug ...
(Date:9/30/2014)...  KemPharm, Inc., a clinical-stage specialty pharmaceutical company ... new molecular entity (NME) prodrugs, announced today that ... issued U.S. Patent No. 8,816,083 to KemPharm for ... Derivatives and Heteroaryl Carboxylic Acid Conjugates of Hydromorphone, ... The patent, which extends through 2032, provides ...
Breaking Biology Technology:Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 2Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 3Surging Diabetic, Obese and Hypertensive Population Drives the Global Cholesterol Testing Market, According to New Report by Global Industry Analysts, Inc. 4CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2
... Non-HDL and apoB measurement helps physicians guide therapy for ... cardiometabolic ... of LDL,non-HDL and apoB are now recognized as valid, accurate ... for patients with,cardiometabolic risk (CMR). The VAP(R) Cholesterol Test (Atherotech, ...
... - CuraGen to receive approximately $45 million in cash, stock and future ... milestone payments ... Provides updated financial guidance for 2008 - ... BRANFORD, Conn., April 22 CuraGen Corporation,(Nasdaq: CRGN ), a clinical-stage ...
... April 22 /Xinhua-PRNewswire/ -- Fufeng Group Limited,("Fufeng" or ... "the Group"; HKEx: 546), a leading vertically integrated,manufacturer ... results for the year ended 31 December 2007., ... sales volume of major,products, the Group,s turnover increased ...
Cached Biology Technology:Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients 2Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients 3CuraGen Sells Ownership of Belinostat to TopoTarget A/S 2CuraGen Sells Ownership of Belinostat to TopoTarget A/S 3CuraGen Sells Ownership of Belinostat to TopoTarget A/S 4CuraGen Sells Ownership of Belinostat to TopoTarget A/S 5Fufeng Announces 2007 Annual Results 2Fufeng Announces 2007 Annual Results 3
(Date:9/30/2014)... reefs face a suite of perilous threats in ... development and climate change, fragile coral ecosystems are ... this trend, some species of corals surrounding the ... natural protector in their tropical environment: coral guard-crabs. ... History,s Smithsonian Marine Station scientist Seabird McKeon and ...
(Date:9/29/2014)... A species of gut bacteria called Clostridium ramosum , ... weight. The work is published this week in mBio ... Microbiology. , A research team from the German Institute ... human gut bacteria including C. ramosum gained weight ... C. ramosum were less obese even when consuming ...
(Date:9/29/2014)... September 29: Between 1970 and 2010 populations of ... globe dropped 52 percent, says the 2014 Living ... (WWF). This biodiversity loss occurs disproportionately in low-income ... high-income countries. , In addition to the precipitous ... to other warning signs about the overall health ...
Breaking Biology News(10 mins):Smithsonian scientists discover coral's best defender against an army of sea stars 2Gut bacteria promote obesity in mice 2Half of global wildlife lost, says new WWF report 2
... Philadelphia, PA, December 12, 2012 Cell aging, or ... physiological response to tumor development. Activated oncogenes are able ... oncogene-induced senescence (OIS) could play a key role in ... unknown mechanism in the regulation of OIS. This study ...
... WINSTON-SALEM, N.C., Dec. 11, 2012 When Teresa Thorn started ... something she,d had years earlier. As the days ... changing, something her co-workers noticed. Finally one Sunday, she and ... Wake Forest Baptist Medical Center, where a battery of tests ...
... research, presented this morning at the 54th Annual ... identified important associations between Plasmodium falciparum ... help researchers identify young children who are more susceptible ... malaria infection alone was considered the important factor, this ...
Cached Biology News:Previously unknown mechanism identified in oncogene-induced senescence 2Vaccine offers promise as post-surgery treatment for pancreatic cancer patients 2Vaccine offers promise as post-surgery treatment for pancreatic cancer patients 3Vaccine offers promise as post-surgery treatment for pancreatic cancer patients 4New research helps predict susceptibility to Burkitt lymphoma 2
MOUSE ANTI BOVINE TROPONIN I...
Ready-to-use; 40mg/ml X-Gal and 32mg/ml IPTG...
Normal donkey serum collected from healthy normal donkeys....
This BioSolution package is excellent for doing fluorescence thermal melt experiments on nucleic acids, studies involving biomolecular interactions, protein folding experiments, and more!...
Biology Products: